wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1349.
1 2 3 4 5 ... 27 Next »

Medicine/Pharmacology
16.02.2018
Novartis new Cosentyx data confirms robust efficacy and quality of life improvements in scalp psoriasis
Majority of patients with scalp psoriasis on Cosentyx (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life á Scalp psoriasis affects 60 million people worldwide - a difficult-to-treat form of psoriasis with a substantial impact on quality of life - á Cosentyx data presented at AAD adds to robust evidence demonstrating sustained efficacy in plaque, nail, palmoplantar and scalp psoriasis as well as psoriatic
Medicine/Pharmacology - Innovation/Technology
15.02.2018
Improving Health of Children in Nigeria
Improving Health of Children in Nigeria
To improve diagnosis and treatment of children under five, Swiss TPH together with the International Committee of the Red Cross (ICRC) developed the electronic decision support tool ALMANACH.
Medicine/Pharmacology - Administration/Government
14.02.2018
Medicine/Pharmacology - Administration/Government
13.02.2018
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis Glatopa 40 mg/mL is a fully substitutable, AP-rated generic
Medicine/Pharmacology
08.02.2018
Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis
US label updated to include Cosentyx (secukinumab) data in moderate-to-severe scalp psoriasis - one of the difficult-to-treat types of psoriasis á Approximately half of all 125 million patients with
Medicine/Pharmacology - Business/Economics
08.02.2018
Life Sciences - Medicine/Pharmacology
31.01.2018
Lab-on-a-chip for tracking single bacterial cells
Lab-on-a-chip for tracking single bacterial cells
Researchers at the Biozentrum of the University of Basel, together with researchers from the Max Planck Institute in Dresden, have set up a novel lab-on-a-chip with accompanying automatic analysis software.
Medicine/Pharmacology
31.01.2018
Cancer Patients: Web-Based Help Improves Quality of Life
Cancer Patients: Web-Based Help Improves Quality of Life
A diagnosis of cancer causes huge psychological stress, but many patients do not receive any psychological support.
Medicine/Pharmacology - Life Sciences
31.01.2018
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL Analysis of 75 patients with m
Medicine/Pharmacology - Administration/Government
26.01.2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) á Advanced Accelerator Applications is a newly established subsidiary of Novartis á Lutathera expands Novartis' n
Medicine/Pharmacology - Business/Economics
26.01.2018
Business/Economics - Medicine/Pharmacology
24.01.2018
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 bi
Medicine/Pharmacology - Life Sciences
24.01.2018
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss Novartis enters into a licensing and supply agre
Life Sciences - Medicine/Pharmacology
23.01.2018
A bacterial powder for quickly stabilizing soils
A bacterial powder for quickly stabilizing soils
EPFL's Laboratory of Soil Mechanics has developed an easily reproducible technique using bacteria and urea to reinforce sandy or gravelly terrain.
Life Sciences - Medicine/Pharmacology
23.01.2018
A bacterial powder for quickly stabilizing gravel surfaces
A bacterial powder for quickly stabilizing gravel surfaces
EPFL's Laboratory of Soil Mechanics has developed an easily reproducible technique using bacteria and urea to reinforce sandy or gravelly terrain.
Medicine/Pharmacology - Physics/Materials Science
22.01.2018
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments LIBERTY is the first mi
Medicine/Pharmacology - Life Sciences
17.01.2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy á EMA granted accelerate
Medicine/Pharmacology - Environment/Sustainable Development
16.01.2018
Novartis new data reinforces superiority of Cosentyx versus Stelara * in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara * in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin cleara
Medicine/Pharmacology - Business/Economics
11.01.2018
Sport Sciences - Medicine/Pharmacology
11.01.2018
Medicine/Pharmacology - Life Sciences
09.01.2018
Novartis advances head-to-head superiority trials of Cosentyx versus Humira * and proposed biosimilar adalimumab**
SURPASS is the firstáhead-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitisá(AS) EXCEED is the firstáhead-to-head superiority trial versus Humira * inápsoria
Medicine/Pharmacology - Physics/Materials Science
04.01.2018
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas New technology allows better testing and monitoring of HIV patients living in rem
Medicine/Pharmacology
04.01.2018
Novartis drug Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Data supporting designation showed over half of treatment-na´ve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of
Medicine/Pharmacology - Life Sciences
03.01.2018
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K
Computer Science/Telecom - Medicine/Pharmacology
28.12.2017
Looking back at 2017 (2/2)
Looking back at 2017 (2/2)
A dazzling victory at the Solar Decathlon, artificial intelligence generating melodies, virtual reality to reduce phantom pain, a robot-fish spy, 12 million francs for a Center of Artificial Muscles...áSome of the EPFL's research and milestones that marked the year 2017.
Life Sciences - Medicine/Pharmacology
27.12.2017
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous-unemotional traits are linked to differences in brain structure in boys, but not girls. This reports a European research team led by the University of Basel and University of Basel Psychiatric Hospital in a study on brain development in 189 adolescents.
Medicine/Pharmacology - Administration/Government
22.12.2017
Novartis’ combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I
Medicine/Pharmacology - Chemistry
22.12.2017
Novartis drug Tasigna is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP á Deep and sustained molecular response included as key eligibility criteria for atte
Medicine/Pharmacology - Life Sciences
21.12.2017
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC
Medicine/Pharmacology - Business/Economics
15.12.2017
Medicine/Pharmacology - Business/Economics
14.12.2017
Medicine/Pharmacology - Life Sciences
12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c
Medicine/Pharmacology - Life Sciences
12.12.2017
Medicine/Pharmacology - Life Sciences
11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.
Medicine/Pharmacology - Life Sciences
10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six
Medicine/Pharmacology - Innovation/Technology
08.12.2017
Life Sciences - Medicine/Pharmacology
08.12.2017
Acrobatic Duo in the Cells
Acrobatic Duo in the Cells
Just like an acrobatic duo, some proteins lend each other stability. Researchers at the Biozentrum of the University of Basel have discovered that the protein ‘Trigger factor' recognizes a partner by instable, flexible domains, to then together form a stable protein duo. The study has been published in the current issue of ‘Nature Communications'.
Medicine/Pharmacology - Computer Science/Telecom
07.12.2017
Using artificial intelligence to advance personalized medicine
Opened less than a year ago, the Swiss Data Science Center - a joint initiative between EPFL and ETH Zurich - has already launched eight research projects in fields ranging from personalized medicine and environmental protection to open science. Each project brings together experts from several disciplines to join forces in tackling some of society's biggest challenges.
Medicine/Pharmacology - Business/Economics
07.12.2017
Medicine/Pharmacology - Life Sciences
07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi
Medicine/Pharmacology
06.12.2017
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to..
Medicine/Pharmacology - Administration/Government
06.12.2017
Personalized Health: National Funding for Basel-led Research Groups
Personalized Health: National Funding for Basel-led Research Groups
Nine research projects involving Basel-based researchers in the field of personalized health are to receive funding from the Swiss government: support will be given to researchers from the University
Medicine/Pharmacology - Innovation/Technology
05.12.2017
"The University of Bern is moving briskly ahead"
At the 183rd Dies academicus of the University of Bern, the rector Christian Leumann broached the issue of the freedom of teaching and research, and took stock of the first "half-time" in the university's strategy.
Medicine/Pharmacology - Life Sciences
05.12.2017
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data.
1 2 3 4 5 ... 27 Next »